Recherche
Enseignement
Solutions
S'identifier
FR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Department of Biopathology and Medical Biotechnology,
Section of Biology and Genetics,
Department of Biopathology and Medical Biotechnology, Section of Biology and Genetics
Marco Giallombardo has not added Biography.
If you are Marco Giallombardo and would like to personalize this page please email our Author Liaison for assistance.
Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells.
Molecular cancer , 2014 | Pubmed ID: 25015105
Nintedanib in non-small cell lung cancer: from preclinical to approval.
Therapeutic advances in respiratory disease Aug, 2015 | Pubmed ID: 25855060
Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21.
Oncotarget Sep, 2015 | Pubmed ID: 26116834
Reduction in mdx mouse muscle degeneration by low-intensity endurance exercise: a proteomic analysis in quadriceps muscle of exercised compared with sedentary mdx mice.
Bioscience reports , 2015 | Pubmed ID: 26182375
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Expert opinion on investigational drugs , 2015 | Pubmed ID: 26457764
In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment.
Oncotarget Jan, 2016 | Pubmed ID: 26701206
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.
Expert opinion on investigational drugs Apr, 2016 | Pubmed ID: 26881293
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice.
Oncotarget Feb, 2016 | Pubmed ID: 26919248
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Critical reviews in oncology/hematology May, 2016 | Pubmed ID: 26960735
Curcumin modulates chronic myelogenous leukemia exosomes composition and affects angiogenic phenotype, via exosomal miR-21.
Oncotarget Mar, 2016 | Pubmed ID: 27050372
University of Palermo
Antwerp University Hospital (UZA)
Marco Giallombardo*,1,2,
Jorge Chacártegui Borrás*,2,3,
Marta Castiglia4,
Nele Van Der Steen3,
Inge Mertens5,6,
Patrick Pauwels7,3,
Marc Peeters8,3,
Christian Rolfo2,3
1Department of Biopathology and Medical Biotechnology, Section of Biology and Genetics, University of Palermo,
2Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital (UZA),
3Center for Oncological Research (CORE), Antwerp University,
4Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo,
5, Flemish Institute for Technological Research (VITO),
6CORE, Campus Groenenborger, Antwerp University,
7Molecular Pathology, Pathology Department, Antwerp University Hospital (UZA),
8Oncology Department, Antwerp University Hospital (UZA)
Confidentialité
Conditions d'utilisation
Politiques
Contactez-nous
RECOMMANDER À LA BIBLIOTHÈQUE
NEWSLETTERS JoVE
JoVE Journal
Collections de méthodes
JoVE Encyclopedia of Experiments
Archives
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Centre de ressources universitaires
Auteurs
Bibliothécaires
Accès
À PROPOS DE JoVE
Copyright © 2024 MyJoVE Corporation. Tous droits réservés.